Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

NCT07136701 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT07136701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
Lead sponsor
Qilu Hospital of Shandong University
Phase
Observational
Overall status
Recruiting
Start date
August 31, 2025
Completion date
July 31, 2027
Enrollment
600 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocine neoplasms (pnets)